Edgewise Therapeutics, Inc.
EWTXNASDAQHealthcare● Active
$34.84
$-0.75(-2.11%)
Market Cap$3.7B
P/E Ratio—
52W High$40.765
52W Low$12.15
Edgewise Therapeutics, Inc. (EWTX) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · EWTX · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Cost of Revenue | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Gross Profit | ($0.00B) | $0.00B | $0.00B | $0.00B | $0.00B |
| Gross Margin %(computed) | — | — | — | — | — |
| Operating Expenses | |||||
| R&D Expenses | $0.15B | $0.13B | $0.09B | $0.05B | $0.03B |
| G&A Expenses | $0.04B | $0.03B | $0.02B | $0.02B | $0.01B |
| Total Operating Expenses | $0.19B | $0.16B | $0.11B | $0.07B | $0.04B |
| Operating Income | ($0.19B) | ($0.16B) | ($0.11B) | ($0.07B) | ($0.04B) |
| Operating Margin %(computed) | — | — | — | — | — |
| Interest Income | $0.02B | $0.03B | $0.01B | $0.00B | $0.00B |
| Interest Expense | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Income Before Tax | ($0.17B) | ($0.13B) | ($0.10B) | ($0.07B) | ($0.04B) |
| Income Tax Expense | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Net Income | ($0.17B) | ($0.13B) | ($0.10B) | ($0.07B) | ($0.04B) |
| Net Margin %(computed) | — | — | — | — | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-1.63 | $-1.45 | $-1.57 | $-1.26 | $-0.86 |
| Wtd Avg Shares | 0.10B | 0.09B | 0.06B | 0.05B | 0.05B |
| EBITDA | ($0.17B) | ($0.16B) | ($0.11B) | ($0.07B) | ($0.04B) |
| EBITDA Margin %(computed) | — | — | — | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · B
Explore more Edgewise Therapeutics, Inc. data
About Edgewise Therapeutics, Inc. (EWTX) Income Statement
Edgewise Therapeutics, Inc. (EWTX) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, EWTX reported revenue of $0.00B, gross profit of ($0.00B) (gross margin —), and net income of ($0.17B) — a net profit margin of —.
Frequently asked questions
EWTX · 4 questionsEdgewise Therapeutics, Inc. (EWTX) reported revenue of $0.00B for 2025, down —% year-over-year.
EWTX revenueEWTX salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08